Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Erasca, Inc.
  6. News
  7. Summary
    ERAS   US29479A1088

ERASCA, INC.

(ERAS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Erasca in Clinical Trial Collaboration Agreement With Pfizer

09/08/2021 | 08:39am EDT

By Michael Dabaie

Erasca Inc. said it is in a clinical trial collaboration and supply agreement with Pfizer Inc.

This agreement would support a clinical proof-of-concept study evaluating ERAS-007 in combination with encorafenib and cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer. The combination would be investigated as part of the Phase 1b/2 HERKULES-3 trial expected to start in the second half of 2021.

Erasca would sponsor the study, and Pfizer would supply encorafenib. The two companies would form a joint development committee to review the clinical trial results.

Worldwide, approximately 1.8 million cases of CRC are diagnosed annually, with BRAF V600E mutations occurring in approximately 10% of these patients, Erasca said. The combination of encorafenib and cetuximab was approved in April 2020 for previously treated patients with BRAF V600E-mutant mCRC.

Write to Michael Dabaie at michael.dabaie@wsj.com

(END) Dow Jones Newswires

09-08-21 0838ET

Stocks mentioned in the article
ChangeLast1st jan.
ERASCA, INC. -2.33% 18.89 Delayed Quote.0.00%
PFIZER, INC. 0.70% 43.16 Delayed Quote.16.44%
All news about ERASCA, INC.
09/27ERASCA : is Named One of Fierce Biotech's “Fierce 15” Biotechnology Companies ..
AQ
09/22ERASCA : Doses First Patient in Phase 1b/2 Trial of ERAS-007 in Gastrointestinal Cancer
MT
09/22ERASCA : Announces First Patient Dosed in HERKULES-3, a Phase 1b/2 Gastrointestinal Cancer..
AQ
09/22Erasca, Inc. Announces First Patient Dosed in HERKULES-3, A Phase 1B/2 Gastrointestinal..
CI
09/20ERASCA, INC.(NASDAQGS : ERAS) added to S&P TMI Index
CI
09/09ERASCA : Doses First Patient in Lung Cancer Treatment Trial
MT
09/09Erasca Announces First Patient Dosed in HERKULES-2 Phase 1b/2 Lung Cancer Master Protoc..
GL
09/09Erasca Announces First Patient Dosed in HERKULES-2 Phase 1b/2 Lung Cancer Master Protoc..
CI
09/08ERASCA : Pfizer Collaborate on Colorectal Cancer Combo Therapy
MT
09/08Erasca in Clinical Trial Collaboration Agreement With Pfizer
DJ
More news
Analyst Recommendations on ERASCA, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -133 M - -
Net cash 2021 90,8 M - -
P/E ratio 2021 -6,18x
Yield 2021 -
Capitalization 2 290 M 2 290 M -
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 102
Free-Float 67,3%
Chart ERASCA, INC.
Duration : Period :
Erasca, Inc. Technical Analysis Chart | ERAS | US29479A1088 | MarketScreener
Technical analysis trends ERASCA, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 18,89 $
Average target price 30,20 $
Spread / Average Target 59,9%
EPS Revisions
Managers and Directors
Jonathan E. Lim Chairman & Chief Executive Officer
David M. Chacko Chief Financial Officer
Michael D. Varney Director, Chairman-Research & Development
Wei Lin Chief Medical Officer
Nik Chetwyn Senior Vice President-Operations
Sector and Competitors
1st jan.Capi. (M$)
ERASCA, INC.0.00%2 290
MODERNA, INC.212.57%131 807
LONZA GROUP AG32.74%61 177
IQVIA HOLDINGS INC.43.38%49 092
SEAGEN INC.-2.12%31 189
CELLTRION, INC.-38.86%25 455